Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plegridy Real-World Effectiveness and Safety Observational Program
NL-OMON47245Phase 4Completed
- Sponsor
- IQVIA
- Start
- Nov 2015
- Modality
- Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta in multiple sclerosis (MS), sponsored by IQVIA. Primary endpoints: Serious adverse events and Clinical no evidence of disease activity. Started Nov 2015; status: completed.
02
Drugs
interferon beta
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON47245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47245.